CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT00458744
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:35:38.615981+00:00
- Published At
- 2014-08-08T00:00:00+00:00
- Record Updated At
- 2014-08-08
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Brain and Central Nervous System Tumors", "Leukemia", "Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2014-08-08"- protocolSection.identificationModule.nctId
"NCT00458744"- protocolSection.identificationModule.officialTitle
"A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias"- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.